<DOC>
	<DOCNO>NCT02700360</DOCNO>
	<brief_summary>A Randomized , Open-Label , Single -Dose , Crossover , Phase I Clinical Trial Evaluate Effect Food Safety , Tolerability Pharmacokinetics EC-18 Oral Administration Healthy Volunteers</brief_summary>
	<brief_title>Evaluation Food Effect Safety , Tolerability , PK EC-18 After Oral Administration Healthy Volunteers</brief_title>
	<detailed_description>In vitro vivo efficacy study clinical trial show EC-18 mode action improve neutropenia promote neutrophil production hematopoietic stem cell time , efficiently control STAT6/Complement 3 ( C 3 ) , suggest potential develop orally administer new drug treatment neutropenia result decrease neutrophil cause administration anticancer agent . This study randomize , open-Label , single -dose , crossover , phase I clinical trial evaluate effect food safety , tolerability pharmacokinetics EC-18 oral administration healthy volunteer</detailed_description>
	<mesh_term>Neutropenia</mesh_term>
	<criteria>1 . Healthy adult age 19 45 year , inclusive , time provide informed consent form 2. body weight : ≥ 55kg ( male ) , ≥ 50kg ( female ) 3 . BMI : 18.5 kg/m2 ≦ BMI &lt; 25.0 kg/m2 [ BMI ( body mass index ) = Body weight ( kg ) / [ height ( ) ] 2 ] 4. female subject , result serum βhCG pregnancy test come negative screening , urine βhCG test come negative take medication period set protocol include one condition . postmenopausal ( natural menstruation least 2 year ) surgically sterile ( hysterectomy bilateral ovariotomy , tubal ligation sterile condition way ) sterility male partner screen ( proof azoospermia vasectomy ) , partner subject . agree use proper continuous method contraception start 14 day ( least ) the1st IND administration 28 day ( least ) last IND administration proper contraception mean physical barrier method include condom , contraceptive diaphragm cervix cap , use hormone include contraceptive oral contraceptive study . 5. male sex life childbearing age female , maintain proper contraception study 28 day last IND administration , agree `` donate sperm '' ( female partner infertility , contraception necessary ) 6 . Written consent voluntary decision participation compliance precaution fully inform completely understanding trial 1 . Hypersensitivity drug contain ingredient investigational product ( EC18 ) similar ingredient ( e.g. , deer antler ) drug ( e.g. , aspirin , antibiotic ) medical history clinically significant hypersensitivity 2 . Active infection chronic local infection base screening test inquiry , verifiable medical record 3 . Serious infection require hospitalization use antibiotic within 30 day prior first dose investigational product , base inquiry verifiable medical record 4 . Presence clinically significant hepatic , renal , gastrointestinal , respiratory , musculoskeletal , endocrine , nervous , blood , cardiovascular , urogenital , psychiatric disorder prior history 5 . ( 1 ) Presenting tuberculosis prior history tuberculosis ( 2 ) positive result QuantiFERON®TB Gold Tube Assay conduct due contact tuberculosis patient within past 3 month sign symptom suspect tuberculosis 6 . Prior history gastrointestinal disorder ( e.g. , Crohn 's disease , ulcer ) surgery ( except simple appendectomy hernia surgery ) may affect drug absorption , etc .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>EC-18</keyword>
	<keyword>Hematology</keyword>
	<keyword>Cancer</keyword>
	<keyword>Neutropenia</keyword>
</DOC>